Selective toxicity of nitracrine to hypoxic mammalian cells
- PMID: 6696822
- PMCID: PMC1976693
- DOI: 10.1038/bjc.1984.34
Selective toxicity of nitracrine to hypoxic mammalian cells
Abstract
Hypoxic cells in solid tumours are resistant to ionizing radiation and may be refractory to treatment by many chemotherapeutic agents. For these reasons the identification of drugs with selective toxicity towards hypoxic cells is an important objective in cancer chemotherapy. Nitroimidazoles such as misonidazole demonstrate such hypoxia-selective toxicity but have very low dose potency. The 1-nitroacridine derivative 1-nitro-9-(dimethylaminopropylamino)acridine (nitracrine) binds reversibly to DNA but also forms covalent adducts with DNA in vivo. We have found nitracrine to be selectively toxic to the Chinese hamster ovary cell line AA8 under hypoxic conditions in culture, with a potency approximately 100,000 times higher than that of misonidazole. The effect of oxygen is not a simple dose-modifying one in this system, probably in part because of rapid metabolic inactivation of nitracrine under hypoxic conditions. Viscometric studies with the mini col E1 plasmid PML-21 confirmed that nitracrine binds to DNA by intercalation, and provided an unwinding angle of 16 degrees (relative to 26 degrees for ethidium). It is proposed that the cytotoxicity of nitracrine under hypoxia is due to reductive metabolism to form an alkylating species, but that intercalation of the chromophore may enhance reactivity towards DNA and hence contribute to the marked enhancement of potency with respect to simple nitroheteroaromatic drugs.
Similar articles
-
Reductive metabolism and hypoxia-selective toxicity of nitracrine.Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1235-8. doi: 10.1016/0360-3016(86)90266-x. Int J Radiat Oncol Biol Phys. 1986. PMID: 3744944
-
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.J Med Chem. 1989 Jan;32(1):31-8. doi: 10.1021/jm00121a007. J Med Chem. 1989. PMID: 2909741
-
Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.J Med Chem. 1996 Jun 21;39(13):2508-17. doi: 10.1021/jm9600104. J Med Chem. 1996. PMID: 8691448
-
Hypoxia-selective radiosensitization of mammalian cells by nitracrine, an electron-affinic DNA intercalator.Int J Radiat Biol Relat Stud Phys Chem Med. 1987 Apr;51(4):641-54. doi: 10.1080/09553008414552171. Int J Radiat Biol Relat Stud Phys Chem Med. 1987. PMID: 3495509
-
Nitracrine and its congeners--an overview.Gen Pharmacol. 1995 May;26(3):473-81. doi: 10.1016/0306-3623(94)00143-b. Gen Pharmacol. 1995. PMID: 7789719 Review.
Cited by
-
Synthesis and in vitro antiproliferative activity against human cancer cell lines of novel 5-(4-methyl-benzylidene)-thiazolidine-2,4-diones.Invest New Drugs. 2008 Oct;26(5):437-44. doi: 10.1007/s10637-008-9130-7. Epub 2008 May 13. Invest New Drugs. 2008. PMID: 18473120
-
Hypoxia-targeted drug delivery.Chem Soc Rev. 2019 Feb 4;48(3):771-813. doi: 10.1039/c8cs00304a. Chem Soc Rev. 2019. PMID: 30575832 Free PMC article. Review.
-
Cyclic Dichalcogenides Extend the Reach of Bioreductive Prodrugs to Harness Thiol/Disulfide Oxidoreductases: Applications to seco-Duocarmycins Targeting the Thioredoxin System.ACS Cent Sci. 2023 Mar 28;9(4):763-776. doi: 10.1021/acscentsci.2c01465. eCollection 2023 Apr 26. ACS Cent Sci. 2023. PMID: 37122469 Free PMC article.
-
Radiosensitization and hypoxic cell toxicity of NLA-1 and NLA-2, two new bioreductive compounds.Jpn J Cancer Res. 1992 Apr;83(4):410-4. doi: 10.1111/j.1349-7006.1992.tb00123.x. Jpn J Cancer Res. 1992. PMID: 1506276 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources